Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 701 to 750 of 1959 results for news

  1. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  2. EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

    NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration

  3. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  4. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse (HTG539)

    Evidence-based recommendations on bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse in adults. This involves replacing weakened or stretched ligaments that support the uterus and hold the pelvic organs in place with mesh tape.

  5. Laparo-endogastric surgery (HTG10)

    Evidence-based recommendations on laparo-endogastric surgery. This involves performing surgery for gastric wall lesions by passing a flexible telescope (endoscope) through the gullet and into the stomach, and a thin tube (laparascope) through a small cut in the upper abdomen.

  6. Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (HTG12)

    Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.

  7. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

  8. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  9. Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

    Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.

  10. NICE HealthTech programme manual (PMG48)

    This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme

  11. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.

  12. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

  13. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

  14. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.

  15. Bisphosphonates for treating osteoporosis (TA464)

    Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.

  16. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  17. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  18. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  19. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

    Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.

  20. Anaphylaxis (QS119)

    This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.

  21. People and communities - putting you at the heart of our work

    NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.

  22. People and communities - putting you at the heart of our work

    NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.

  23. Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence (HTG262)

    Evidence-based recommendations on endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence. This involves applying radiofrequency energy to the anal wall, with the aim of inducing muscle changes to improve muscle tone and help control bowel movement.

  24. Sacral nerve stimulation for faecal incontinence (HTG61)

    Evidence-based recommendations on sacral nerve stimulation for faecal incontinence. This involves using electrodes inserted under the skin to produce pulses of electricity thought to affect the nerves controlling the lower part of the bowel and the anal sphincter.

  25. Transvaginal laser therapy for urogenital atrophy (HTG582)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  26. Transvaginal laser therapy for stress urinary incontinence (HTG581)

    Evidence-based recommendations on transvaginal laser therapy for urinary stress incontinence. This involves using a laser in the vagina to strengthen the vaginal walls, to help support the bladder and reduce symptoms of urinary stress incontinence.

  27. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  28. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  29. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  30. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  31. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  32. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

  33. NICE says paperclip-sized sensor could help thousands monitor heart condition from home

    A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.

  34. Bioprosthetic plug insertion for anal fistula (HTG528)

    Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in place.

  35. Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

    Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.

  36. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

  37. PLGF-based testing to help diagnose suspected preterm pre-eclampsia (HTG630)

    Evidence-based recommendations on placental growth factor (PLGF)-based testing to help diagnose suspected preterm pre-eclampsia. The tests are: DELFIA Xpress PLGF 1-2-3, DELFIA Xpress sFlt-1/PLGF 1-2-3 ratio, Elecsys immunoassay sFlt-1/PLGF ratio, Triage PLGF Test.

  38. Using NICE guidance in social work: scenarios for principal social workers

    proposing to relocate locality teams to a number of health centres, as part of a new integrated support service. The team managers are...

  39. Endovenous laser treatment of the long saphenous vein (HTG26)

    Evidence-based recommendations on endovenous laser treatment of the long saphenous vein. This involves using laser and heat to seal up the vein.

  40. Aflibercept for treating choroidal neovascularisation (TA486)

    Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.

  41. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  42. End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia (MIB10)

    NICE has developed a medtech innovation briefing (MIB) on End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia .

  43. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MIB174)

    NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .

  44. Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (HTG721)

    Evidence-based recommendations on endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. This involves using heat to destroy the lining of the duodenum to encourage a new lining to grow.

  45. Transperineal template biopsy and mapping of the prostate (HTG237)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  46. Bone-anchored cystourethropexy (HTG6)

    Evidence-based recommendations on bone-anchored cystourethropexy for treating stress urinary incontinence in women. Bone-anchored cystourethropexy is a minimally invasive bladder neck needle suspension procedure.

  47. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.

  48. NICE Advice: working on your objectives

    If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.

  49. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

  50. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.